| Literature DB >> 22762351 |
Victoria Borg Debono1, Shiyuan Zhang, Chenglin Ye, James Paul, Aman Arya, Lindsay Hurlburt, Yamini Murthy, Lehana Thabane.
Abstract
BACKGROUND: Randomized controlled trials (RCTs) are routinely used in systematic reviews and meta-analyses that help inform healthcare and policy decision making. The proper reporting of RCTs is important because it acts as a proxy for health care providers and researchers to appraise the quality of the methodology, conduct and analysis of an RCT. The aims of this study are to analyse the overall quality of reporting in 23 RCTs that were used in a meta-analysis by assessing 3 key methodological items, and to determine factors associated with high quality of reporting. It is hypothesized that studies with larger sample sizes, that have funding reported, that are published in journals with a higher impact factor and that are in journals that have adopted or endorsed the CONSORT statement will be associated with better overall quality of reporting and reporting of key methodological items.Entities:
Year: 2012 PMID: 22762351 PMCID: PMC3407517 DOI: 10.1186/1471-2253-12-13
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Description of overall quality of reporting items
| 1. Title or Abstract | Identification as a randomized trial in the title and a structured summary of the trial design, methods, results, and conclusions. |
| 2. Background | Scientific background and explanation of rationale. |
| 3. Objectives | Specific objectives or hypotheses. |
| 4. Participants | Eligibility criteria for participants. Settings and locations where the data were collected |
| 5. Interventions | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered. |
| 6. Outcomes | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed. |
| 7. Sample Size | How sample size was determined. When applicable, explanation of any interim analyses and stopping guidelines. |
| 8. Randomization: Sequence Generation | Method used to generate the random allocation sequence Type of randomisation; details of any restriction (such as blocking and block size). |
| 9. Randomization: Implementation | There is mention of: Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions? |
| 10. Statistical Methods | Statistical methods used to compare groups for primary and secondary outcomes. Methods for additional analyses, such as subgroup analyses and adjusted analyses. |
| 11. Participants Flow | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome. For each group, losses and exclusions after randomisation, together with reasons. |
| 12. Recruitment | Dates defining the periods of recruitment and follow-up. Why the trial ended or was stopped. |
| 13. Baseline Data | A table showing baseline demographic and clinical characteristics for each group. |
| 14. Outcomes and Estimates | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval). For binary outcomes, presentation of both absolute and relative effect sizes is recommended. |
| 15. Harms | All important harms or unintended effects in each group |
| 16. Ethical Issues | The approval of an ethics committee and obtaining of informed consent from participants are stated |
| 17. Flowchart | A flowchart of participants in each stage of the RCT (randomization, allocation, follow-up, and analysis for primary outcome) is provided |
Please note that the description describing each CONSORT item used are taken directly from the “CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials” article [1].
Overall Quality of Reporting: Rating using items from the CONSORT Statement and two additional items
| 0 | (0, 8) | |
| 22 | (20, 23) | |
| 23 | (15, 23) | |
| 6 | (2, 10) | |
| 23 | (15, 23) | |
| 9 | (5, 14) | |
| 19 | (15, 22) | |
| 8 | (4, 13) | |
| 1 | (0, 3) | |
| 17 | (13, 21) | |
| 12 | (7, 17) | |
| 3 | (0, 6) | |
| 22 | (20, 23) | |
| 11 | (6, 16) | |
| 18 | (14, 22) | |
| 21 | (18, 23) | |
| 2 | (0, 5) | |
CI: Confidence Interval.
*For item that has non-zero event, the 95% CI was approximated by assuming the number of events followed a Binomial distribution; for item that has zero event, the 95% CI was approximated by the rule of three [49].
Reporting Quality of Key Methodology Items
| Allocation was considered appropriate in a RCT study if one of the following allocation methods were reported; 1) central randomization, 2) numbered, coded vehicles, and 3) opaque, sealed, and sequentially numbered envelopes | 8 | (4, 13) | |
| Blinding was considered to have occurred if at least one specific group was explicitly reported as blinded if there was a blinding feasibility issue. In cases where blinding was not an issue, at least two groups must have been explicitly reported as blinding to qualify as appropriate blinding. | 5 | (1, 9) | |
| Intention to treat was defined as the inclusion of all patients randomly assigned in the analysis, regardless of whether they actually satisfied the entry criteria, the treatment actually received, and subsequent with withdrawal or protocol deviations. | 9 | (5, 14) | |
CI: Confidence Interval.
*For item that has non-zero event, the 95% CI was approximated by assuming the number of events followed a Binomial distribution; for item that has zero event, the 95% CI was approximated by the rule of three [49].
Regression analysis for the Overall Reporting Qualityin 23 RCTs
| Sample Sizeb | 0.791 | (0.326, 1.919) | 0.605 |
| Impact Factor | 0.934 | (0.722, 1.208) | 0.604 |
| Journal adopted CONSORT Statement at the time of data collection. | 0.938 | (0.671, 1.312) | 0.708 |
| Funding reported | 1.262 | (0.837, 1.903) | 0.266 |
CI: Confidence Interval; IRR: Incidence Rate Ratio.
a Maximum Possible Score for the Overall Reporting Quality = 15.
b The sample size variable was log(10) transformed. The value is an expression of the change in the average of the OQRS due to one unit increase in sample size in the log scale.
Regression analysis for the Key Methodology Item Scorein 23 RCTs
| Sample Sizeb | 2.383 | (0.191, 29.665) | 0.500 |
| Impact Factor | 2.022 | (0.742, 5.509) | 0.169 |
| Journal adopted CONSORT Statement at the time of data collection. | 0.517 | (0.148, 1.803) | 0.301 |
| Funding reported | 1.766 | (0.619, 5.040) | 0.288 |
CI: Confidence Interval; IRR: Incidence Rate Ratio.
a Maximum Possible Score for the Key Methodology Item = 3.
b The sample size variable was log(10) transformed. The value is an expression of the change in the average of the KMIS due to one unit increase in sample size in the log scale.